Loading organizations...
Loading organizations...
Developing oncolytic virus therapies for cancer treatment.
Vyriad has raised $54.5M across 2 funding rounds.
Vyriad has raised $54.5M in total across 2 funding rounds.
Vyriad has raised $54.5M in total across 2 funding rounds.
Vyriad's investors include Harry Stine, Mayo Clinic, Mirae Asset, Regeneron Pharmaceuticals, Southeast Minnesota Capital Fund.
Vyriad has raised $54.5M across 2 funding rounds. Most recently, it raised $25.0M Series B Extension in December 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 23, 2025 | $25.0M Series B Extension | Harry Stine | |
| May 17, 2022 | $29.5M Series B | Harry Stine | Mayo Clinic, Mirae Asset, Regeneron Pharmaceuticals, Southeast Minnesota Capital Fund |